World Vaping Alliance Launches Campaign to Save Lives

Oct.26.2022
World Vaping Alliance Launches Campaign to Save Lives
The World Vape Alliance begins a European tour to promote the message that e-cigarettes can save millions of lives.

The World Vaping Alliance (WVA) is back. After launching its first campaign in the summer of 2021, it is once again spreading the message across Europe that electronic cigarettes can save millions of lives. This time, it began outside the European Parliament in Strasbourg.


The movement began for the first time in the summer of 2021 when WVA launched a new graffiti mural outside the European Parliament with a clear message: supporting electronic cigarettes can save the lives of 19 million people in Europe.


During the press conference, e-cigarette enthusiasts from across Europe and European Parliament member Peter Liese were in attendance. WVA Director Michael Landl emphasized the potential of e-cigarette products, stating that "vaping has the potential to save the lives of 19 million people in Europe." The following day, the European Parliament's Committee on Environment, Public Health and Food Safety (ENVI) met to discuss proposals aimed at reducing the harm caused by smoking. If they endorse smokers using e-cigarettes as a tool to combat smoking, they have the opportunity to make history and save lives. The message conveyed to them was clear - choose science and save lives.


WVA proposed the "Electronic Cigarette Products Directive" with its recommendations.


Meanwhile, at the start of this election campaign, representatives from WVA met with several members of the European Parliament to introduce their "Electronic Cigarette Product Directive" and demonstrate how e-cigarettes can be utilized as a tool to fully realize their potential for public health. Additionally, an art installation called "Don't Let 19 Million People Die" will be spread across ten cities in six countries from October to November 2022.


In addition, this movement will coincide with the ongoing review of tobacco legislation and the Tobacco Products Directive (TPD) across Europe. The WVA has previously participated in a public call by the European Commission to provide evidence against flavor bans and excessive regulation. Through this movement, the organization aims to once again give voice to the European smoking community and encourage smokers to share their experiences in quitting smoking.


Michael Randall, head of WVA, emphasized that managing smoking can save lives. "By supporting e-cigarette users, we can combat smoking through reasonable regulation and save the lives of 19 million people. The EU's call for evidence has reached a record-breaking 24,000 people, indicating that consumers want to reduce tobacco harm, and e-cigarettes have proven to be the most successful option. The EU needs to end the ongoing discussion about smoking and e-cigarettes that is burdensome and easily obtainable. It is time for the EU to fully support reducing tobacco harm and making e-cigarette users its core.


Statement:


This article is compiled based on third-party information and is intended solely for industry exchange and learning.


This article does not represent the views of 2FIRSTS and they cannot confirm the authenticity or accuracy of the content. The translation of this article is intended solely for industry communication and research purposes.


Due to limitations in translation ability, the translated article may not fully reflect the same meaning as the original. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government regarding any domestic, Hong Kong, Macau, Taiwan, or foreign statements or positions.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

China Discloses First Criminal Case Over Counterfeit Vapes Disguised as “Medical Nebulizers” and “Zero-Nicotine” Products
China Discloses First Criminal Case Over Counterfeit Vapes Disguised as “Medical Nebulizers” and “Zero-Nicotine” Products
Chinese authorities have disclosed the country’s first reported criminal case involving counterfeit vapes marketed as “medical nebulizers” and “zero-nicotine” products. Authorities determined that the products involved were counterfeit vapes and pursued criminal charges for producing and selling counterfeit goods. According to the report, the case resulted in the seizure of 347,000 counterfeit vape pods and 53,700 vape devices, with physical goods valued at 22.13 million yuan.
Aug.04
NATO Executive Director David Spross Sees U.S. Vape Regulation Improving, Calls for More PMTA Authorizations and Warns of 2027 State Tax Pressure
NATO Executive Director David Spross Sees U.S. Vape Regulation Improving, Calls for More PMTA Authorizations and Warns of 2027 State Tax Pressure
The National Association of Tobacco Outlets is calling for more FDA marketing authorizations, greater transparency in the PMTA process and continued enforcement against unauthorized e-cigarettes, even as its executive director, David Spross, points to recent regulatory developments as signs of progress. At the state level, excise taxes, flavor restrictions and vapor product directories remain major issues for tobacco retailers. By August 2026, 17 states had enacted laws establishing state-managed e-cigarette directories or similar systems.
Innovation
Sep.29 by 2Firsts Perspectives
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation Limited has been granted a Chinese invention patent covering 6-methylnicotine salt formulations and their use in oral and vaping products. The technology forms salts between 6-methylnicotine and alicyclic carboxylic acids, with granted claims extending to oral products, atomization substrates and electronic atomization devices. Applicant-generated tests reported differences in oxidation stability, in-vitro cytotoxicity and aerosol heavy-metal performance compared with selected benzoate or lactate controls. HG Innovation is directly linked to the broader IMiracle and ELFBAR business network.
Sep.04
Product | JT to Launch MEVIUS Tropical Option in Japan, Expanding Ploom Tobacco Stick Lineup to 32
Product | JT to Launch MEVIUS Tropical Option in Japan, Expanding Ploom Tobacco Stick Lineup to 32
Japan Tobacco (JT) will launch MEVIUS Tropical Option, a new tobacco stick for Ploom, nationwide in Japan from October 6, 2026. The capsule-format product combines mango-oriented sweetness with menthol cooling, adding a tropical flavor to the MEVIUS Ploom tobacco-stick lineup for the first time. Each pack contains 20 sticks and will launch at JPY 590. The product is compatible with all Ploom devices, and its addition will expand the Ploom tobacco-stick portfolio to 32 variants.
Sep.08
UK PM Andy Burnham Reshapes Vape Retail Rules as Licensing Could Raise Barriers for New Shops
UK PM Andy Burnham Reshapes Vape Retail Rules as Licensing Could Raise Barriers for New Shops
UK Prime Minister Andy Burnham is pushing a high street reform agenda that could give local authorities greater powers over commercial activity, including vape retail. The reforms could involve expanded planning powers and a potential vape retail licensing system, allowing councils to play a larger role in store locations and market access. The measures are part of the UK’s broader shift toward tighter vape regulation, although no nationwide vape retail restrictions have yet been implemented.
Aug.11
FDA Authorizes Four More Nicotine Pouches as Review Pilot Expands Beyond Initial Decisions
FDA Authorizes Four More Nicotine Pouches as Review Pilot Expands Beyond Initial Decisions
The FDA has authorized four additional on! nicotine pouches, bringing the U.S. total to 30. The decision marks another outcome of the agency’s nicotine pouch review pilot, whose communication and review practices are now being applied more broadly across the category. It also extends Helix’s authorized portfolio from on! PLUS to the earlier on! line. Yet all FDA-authorized nicotine pouches still come from subsidiaries of PMI or Altria, underscoring how concentrated U.S. regulatory access remains.
Aug.05